Edition:
United Kingdom

Aileron Therapeutics Inc (ALRN.OQ)

ALRN.OQ on NASDAQ Stock Exchange Global Market

0.89USD
9:00pm BST
Change (% chg)

$0.03 (+2.89%)
Prev Close
$0.87
Open
$0.85
Day's High
$0.89
Day's Low
$0.85
Volume
12,107
Avg. Vol
42,371
52-wk High
$6.17
52-wk Low
$0.52

Latest Key Developments (Source: Significant Developments)

Armistice Capital Reports 8 Pct Passive Stake In Aileron Therapeutics Inc As Of March 29
Monday, 8 Apr 2019 

April 8 (Reuters) - Aileron Therapeutics Inc ::ARMISTICE CAPITAL LLC REPORTS 8.0 PERCENT PASSIVE STAKE IN AILERON THERAPEUTICS INC AS OF MARCH 29 - SEC FILING.  Full Article

Aileron Therapeutics Announces Pricing Of $26 Mln Private Placement
Friday, 29 Mar 2019 

March 29 (Reuters) - Aileron Therapeutics Inc ::AILERON THERAPEUTICS ANNOUNCES PRICING OF $26M PRIVATE PLACEMENT.AILERON THERAPEUTICS - ENTERED INTO SECURITIES PURCHASE DEAL WITH GROUP OF INSTITUTIONAL ACCREDITED INVESTORS OF $26 MILLION OF AILERON STOCK, WARRANTS.AILERON THERAPEUTICS - SELLING IN PRIVATE PLACEMENT 11.8 MILLION UNITS FOR A COMBINED PRICE OF $2.01 PER UNIT.  Full Article

Aileron Therapeutics Says Loss Per Share For 3 Months Ended Dec. 31, 2018 Was $0.48
Friday, 29 Mar 2019 

March 29 (Reuters) - Aileron Therapeutics Inc ::AILERON THERAPEUTICS INC - LOSS PER SHARE FOR 3 MONTHS ENDED DECEMBER 31, 2018 WAS $0.48.  Full Article

Aileron Enters Clinical Trial Collaboration With Pfizer
Tuesday, 27 Nov 2018 

Nov 27 (Reuters) - Aileron Therapeutics Inc ::AILERON ENTERS CLINICAL TRIAL COLLABORATION WITH PFIZER TO EVALUATE ALRN-6924 IN COMBINATION WITH IBRANCE® (PALBOCICLIB) IN MDM2-AMPLIFIED CANCERS.AILERON THERAPEUTICS INC - AILERON EXPECTS THIS PHASE 1B TRIAL TO START ENROLLING PATIENTS WITH SOLID TUMORS IN Q1 OF 2019.AILERON THERAPEUTICS INC - PFIZER WILL PROVIDE DRUG SUPPLY IN SUPPORT OF TRIAL.  Full Article

Aileron Therapeutics Q3 Loss Per Share $0.50
Wednesday, 7 Nov 2018 

Nov 7 (Reuters) - Aileron Therapeutics Inc ::AILERON THERAPEUTICS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.50.Q3 EARNINGS PER SHARE VIEW $-0.56 -- THOMSON REUTERS I/B/E/S.  Full Article

Aileron Therapeutics Files For Mixed Shelf Of Upto $150 Mln
Tuesday, 7 Aug 2018 

Aug 7 (Reuters) - Aileron Therapeutics Inc ::AILERON THERAPEUTICS INC FILES FOR MIXED SHELF OF UPTO $150 MILLION - SEC FILING.  Full Article

Aileron Therapeutics Names John Longenecker As Interim CEO
Tuesday, 15 May 2018 

May 15 (Reuters) - Aileron Therapeutics Inc ::AILERON THERAPEUTICS ANNOUNCES CHANGES TO MANAGEMENT.AILERON THERAPEUTICS INC - JOHN P. LONGENECKER HAS BEEN NAMED INTERIM CHIEF EXECUTIVE OFFICER.AILERON THERAPEUTICS INC - JOSEPH A. YANCHIK III HAS RESIGNED AS PRESIDENT AND CHIEF EXECUTIVE OFFICER AND AS A MEMBER OF CO'S BOARD.  Full Article

Aileron Therapeutics Q1 Loss Per Share $0.52
Wednesday, 9 May 2018 

May 9 (Reuters) - Aileron Therapeutics Inc ::AILERON THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.52.Q1 EARNINGS PER SHARE VIEW $-0.50 -- THOMSON REUTERS I/B/E/S.  Full Article

Aileron Therapeutics Reports Q4 Loss Of $0.47 Per Share
Monday, 2 Apr 2018 

April 2 (Reuters) - Aileron Therapeutics Inc ::AILERON THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.47.Q4 EARNINGS PER SHARE VIEW $-0.44 -- THOMSON REUTERS I/B/E/S.GAAP LOSS PER SHARE $0.47.BELIEVES CASH, CASH EQUIVALENTS, INVESTMENTS AS OF DEC 31 TO ENABLE CO TO FUND OPERATING EXPENSES, CAPEX INTO H2 2019.  Full Article

Aileron Therapeutics posts Q3 loss of $0.45 per share
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Aileron Therapeutics Inc :Aileron therapeutics reports third quarter 2017 financial results.Q3 loss per share $0.45.Q3 earnings per share view $-0.35 -- Thomson Reuters I/B/E/S.Cash, cash equivalents and investments as of Sept. 30, 2017 were $56.9 million, compared to $20.7 million as of December 31, 2016​.Qtrly ‍non-gaap net loss per share attributable to common stockholders $0.43​.  Full Article